Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer

NCT ID: NCT07125391

Last Updated: 2025-08-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-20
• Study Completion Date: 2027-06-30

Brief Summary

Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is the standard treatment for patients with advanced ovarian cancer. However, most of the ovarian cancer is stage Ⅲ and above, and there may be a certain degree of organ metastasis. Preclinical studies have found that the stress of melanoma block beta adrenergic signals in mice, which USES beta blockers, checkpoint will enhance resistance to PD - 1 the activity of the inhibitor, to improve the treatment of mice on the immune response. Non-selective β-blockers can also improve the efficacy of melanoma immunotherapy. Retrospective studies have shown that incidental use of β-blockers in combination with antiangiogenic agents, chemotherapy, and immune therapy can prolong DFS, PFS, and OS in cancer patients. A large, multicenter retrospective study found that ovarian cancer patients who took nonselective β-blockers for hypertension had better survival than those who did not. In conclusion, this study aims to explore new auxiliary chemotherapy combined propranolol treatment of high efficacy and safety of ovarian cancer, provide more evidence-based basis for clinic.

Detailed Description

The study included patients with inoperable stage III or IV ovarian cancer who were initially treated in FIGO stage III or IV. "A phase II trial to explore the efficacy and safety of neoadjuvant chemotherapy plus propranolol in patients with histologically confirmed high-grade serous ovarian cancer." Na row standard subjects were divided into 2 groups: Queue A accept propranolol hydrochloride (20 mg, BID, QD), paclitaxel/paclitaxel liposome (135-175 mg/m2, d1, Q3W) and carboplatin (AUC = 4-5, d1, Q3W), neoadjuvant therapy cycle, A total of 3-4 Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy. Queue B receive paclitaxel/paclitaxel liposome (135-175 mg/m2, d1, Q3W) and carboplatin (AUC = 4-5, d1, Q3W), neoadjuvant therapy cycle, a total of 3-4 line then intermittent tumor cells to destroy the loss (interval debulking surgery, IDS); Patients will accept the tumor assessment before the surgery, postoperative by researchers according to aid in the treatment of ovarian cancer guidelines take corresponding.

Conditions

Ovarian Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Control group

Received paclitaxel/paclitaxel liposome (135 - 175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W), neoadjuvant therapy for 3 - 4 cycles, followed by interval debulking surgery (IDS)

Group Type: OTHER

Cohort A

Intervention Type: DRUG

received propranolol hydrochloride (20mg, BID, QD), paclitaxel/paclitaxel liposome (135-175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W) for 3-4 cycles of neoadjuvant therapy. Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy

Interventions

Cohort A

received propranolol hydrochloride (20mg, BID, QD), paclitaxel/paclitaxel liposome (135-175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W) for 3-4 cycles of neoadjuvant therapy. Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written informed consent was obtained before any trial-related procedures were performed.
• Women, 18 to 75 years old;
• FIGO stage for stage III or IV, including not surgery in patients with stage III or IV beginning for ovarian cancer; Histopathology confirmed high-grade serous ovarian cancer.
• According to the response evaluation criteria in 1.1 (RECIST1.1) definition, patients must have a measurable lesions
• Agreed to provide the participants formalin fixed and tumor tissue specimens or fresh biopsy tissue tumor lesions markers detection
• ECOG score 0-1 points
• Expected survival time 6 months or more
• Enough organ function, without severe hematopoietic dysfunction and heart, lung, liver, kidney dysfunction, and immune deficiency, participants need to satisfy the following laboratory indicators

• hemoglobin (HGB) 90 g/L or higher
• Neutrophils (NEUT) acuity 1.5 x 109 / L or white blood cell count (WBC) or 3 x 109 / L
• Platelet (PLT) or 90 x 109 / L
• Nmda aminotransferase (AST) 2.5 x ULN or less
• Alanine aminotransferase (ALT) 2.5 x ULN or less
• Total bilirubin (TBIL) 1.5 x ULN or less
• Serum creatinine (SCr) 1.0 x ULN or less
• Potential fertility women in the group of 7 days before the serum or urine HCG were negative (postmenopausal women considered must be at least 12 months of amenorrhea fertility; Pregnancy tests are not required for women with documented tubal ligation)
• Potential fertility women are willing to take in the experiment of the medical contraception

Exclusion Criteria

• Malignant diseases other than ovarian cancer (excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, and/or radical resection in situ carcinoma) diagnosed within 5 years before the first dose
• Current are participating in clinical research and treatment of intrusive, or within 4 weeks before the first dose received study used drugs or other treatments
• Always received pelvic radiotherapy and systemic chemotherapy for ovarian cancer, tumor targeting therapy, immune therapy
• Need treatment of symptomatic or non-control brain metastasis at the same time, including but not limited to, surgery, radiation and/or corticosteroids, or with the clinical manifestations of spinal cord compression
• Current use of oral or intravenous beta blockers (atenolol, peso parlour, carvedilol and labetalol, metoprolol, than the parlour, his law such as beta blockers) cannot safely use of propranolol
• Patients with contraindications to β-blockers were excluded according to the contraindications in the propranolol package insert.
• Patients were receiving systemic glucocorticoids (excluding topical glucocorticoids by nasal spray, inhalation, or other route) or any other form of immunosuppressive therapy within 7 days before the first study dose; Note: allows the use of physiological doses of corticosteroids (10 mg/day or less prednisone or equivalent drugs)
• Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
• Patients who were allergic to the active ingredient or excipients of propranolol hydrochloride in this study
• Have not fully recovered from any intervention-related toxicity and/or complications before starting treatment (i.e., ≤ grade 1 or baseline, excluding fatigue or alopecia)
• Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive)
• Hepatitis b patients with known
• Activity of HCV infection subjects (HCV antibody positive and HCV - RNA levels higher than the detection limit)
• For the first time to give medicine before (1 cycle, day 1) vaccinated live vaccine within 30 days
• Pregnant or lactating women
• Any serious or uncontrolled systemic disease, such as

• resting electrocardiogram (ecg) in rhythm, conduction, or have a significant and severe symptoms to appear on the form is hard to control the exceptions, such as complete left bundle branch block, Ⅱ degrees above heart block, ventricular arrhythmia or atrial fibrillation
• Unstable angina and congestive heart failure, New York heart association (NYHA) classification of grade 2 or more chronic heart failure
• Within 6 months before the selected treatment had any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, etc.
• First dose exist within 1 year before need to glucocorticoid treatment of infectious pneumonia history, or the current clinical activity interstitial lung disease; Active tuberculosis
• There need systemic treatment of active or failure to control the infection
• Clinical activity diverticulitis, abdominal abscess, gastrointestinal obstruction
• Liver disease such as cirrhosis of the liver, decompensated liver disease, acute or chronic active hepatitis
• Mental disorders and unable to cooperate with treatment
• Any medical history or evidence of illness, abnormal treatment or laboratory values, or other conditions that might interfere with the results of the trial or prevent full participation in the study, or any other potential risk that might be considered by the investigator to be inappropriate for enrollment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Bai-Rong Xia

OTHER

Sponsor Role: lead

Responsible Party

Bai-Rong Xia

Chairman of Department of Gynaecology Surgery

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Bai-Rong Xia, Doctor

Role: STUDY_CHAIR

Anhui Provincial Cancer Hospital

Locations

Anhui Cancer Hospitail

Hefei, Anhui, China

Site Status: RECRUITING

Countries

China

Central Contacts

Yao Xia, Doctor

Role: CONTACT

xiabairong9999@126.com

+8118604516165

Facility Contacts

Bai-Rong Xia, Doctor

Role: primary

xiabairong9999@126.com

+8118604516165

Role: backup

xiabairong9999@126.com

Other Identifiers

2025-LLYJ-0015

Identifier Type: -

Identifier Source: org_study_id